Skip to Contents
뒤로가기
Hanmi pharmaceutical
Hanmi pharmaceutical
Hanmi pharmaceutical
About Us
Hanmi
Founder’s Story
History
Affiliates
Location
ESG
Hanmi ESG
E (Environment)
S (Social)
G (Governance)
ESG Report
Responsibility
CSR
Ethical Management
PR/IR
Press Releases
IR
Stock Information
Financial Information
Science
Science
Science
Hanmi R&D
Research Areas
Technology
Overview
Long-acting platform technology
Bispecific antibody platform technology
Cancer Research
IMD·New Formulation
Pipeline
Pipeline Snapshot
Innovative R&D Pipeline
Focused Pipeline
Business
Business
Business
Open Innovation
CDMO
Product
Contact
Contact
Contact
Contact Us
ENG
open
KOR
ENG
open
KOR
Hanmi pharmaceutical
About Us
Hanmi
Founder’s Story
History
Affiliates
Location
ESG
Hanmi ESG
E (Environment)
S (Social)
G (Governance)
ESG Report
Responsibility
CSR
Ethical Management
PR/IR
Press Releases
IR
Stock Information
Financial Information
Science
Hanmi R&D
Research Areas
Technology
Overview
Long-acting platform technology
Bispecific antibody platform technology
Cancer Research
IMD·New Formulation
Pipeline
Pipeline Snapshot
Innovative R&D Pipeline
Focused Pipeline
Business
Open Innovation
CDMO
Product
Contact
Contact
©Hanmi Pharm.Co.,Ltd. All Rights Reserved.
HOME
Science
Pipeline
Hanmi R&D
Research Areas
Technology
Pipeline
Expanded Access Policy
Pipeline Snapshot
Pipeline Snapshot
Innovative R&D Pipeline
Focused Pipeline
Hanmi Pharmaceutical’s Innovative R&D Pipeline
.
Pipeline Snapshot
Innovative R&D Pipeline
Pipeline Snapshot
All
Partnership Opportunity
Existing Partnerships
Phase 3/Approved
Phase 2
Phase 1
Preclinical
Status as of May
2023
print
Preclinical
Phase 1
Phase 2
Phase 3/Approved
Close Popup